Mike Hosking Breakfast

We are into the age of testing gene editing on humans when it comes to looking into heart disease issues. Earlier this month a New Zealander was the first person to be injected with gene-editing instructions to try and modify a single part of their DNA to stop it producing bad cholesterol. It has been used on monkeys in the past, which resulted in a 70 percent reduction in cholesterol levels. Dr. Andrew Bellinger is the chief scientific and medical officer of Verve Therapeutics and he joined Mike Hosking. LISTEN ABOVE